CDK4 R24C

CI-VAR-00003790Explore in graph →NP_000066.1:p.Arg24CysNM_000075.3:c.70C>TClinVar 16928 CIViC 556 rs11547328

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Cutaneous Melanoma1
CDK4 R24C	Palbociclib	Predictive	D	Supports Sensitivity Response	1	accepted	EID1376 In a cohort of 143 patients with primary invasive melanoma, copy-number gain of CDK4 was observed (FISH) in 37% of cases. PD0332991 efficacy (proliferation assay) was assessed in a panel of 47 melanom… (full text at CIViC) PMID 24495407 · Young et al., 2014 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
16928	Pathogenic	criteria provided, multiple submitters, no conflicts	2	Melanoma, cutaneous malignant, susceptibility to, 3; Familial melanoma; Hereditary cancer-predisposing syndrome	germline	7	Jan 20, 2026	clinvar